Document is current

Any future updates will be listed below

A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer

Crossref DOI link: https://doi.org/10.1007/s00280-015-2906-5

Published Online: 2015-11-12

Published Print: 2016-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark